Biologics restrictions result in lost savings

Restricting access to samples of generic biological drugs would lead to nearly $140 million in lost savings for every $1 billion in biologics sales, Matrix Global Advisors said.

Want to Read More?

This content is available only to registered users. Log in to read the rest of this article or create a free account.

Login or Register to post a comment.